# Cellbricks Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellbricks-therapeutics

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.cellbricks-therapeutics.com
- Total disclosed funding: $8.1M
- Latest round: Seed (Mar 25, 2026)
- Investors on record: 3

## About

Cellbricks Therapeutics, based in Berlin, Germany, develops innovative cell-based tissue therapeutics to address conditions stemming from tissue dysfunction, focusing on restoring organ functionality and soft tissue defects.Founded in 2016 and headquartered in Berlin, Germany, Cellbricks Therapeutics specializes in advanced biofabrication of human tissues. The company has raised a total of EUR 7.00 mn in funding across three investment rounds, with the latest being a SEED round led by Silicon Roundabout, which raised EUR 7.00 mn. The firm has not undergone any significant pivots in its business strategy.Cellbricks Therapeutics specializes in the development of advanced, cell-based human tissue therapeutics aimed at addressing conditions linked to tissue dysfunction. Their flagship products utilize a proprietary light-based biofabrication system, which combines human cells with custom biomaterials to produce biofabricated tissues at scale. This innovative approach seeks to restore lost tissue and organ function for patients suffering from various diseases, with a particular focus on soft tissue defects and organ functionality. The company’s solutions have been validated in vivo, ensuring functionality, scalability, and compatibility with the human immune system. Cellbricks primarily serves healthcare providers and research institutions across Europe and North America, positioning its offerings to meet the growing demand for reliable tissue regeneration solutions in these regions.Cellbricks Therapeutics generates revenue through partnerships with healthcare providers and research institutions, facilitating the sale of its human tissue therapeutics. The company structures transactions on a B2B model, with clients purchasing its biofabricated tissue products for use in clinical applications and research settings. These transactions are based on negotiated agreements that detail quantities, pricing, and service terms. While specific pricing for individual products has not been disclosed, the revenue model encompasses direct sales of therapeutic products alongside potential collaborations for research and development projects. The company's recent capital raise of EUR 7.00 mn indicates a commitment to advancing its technology and expanding its clinical offerings, enhancing its revenue-generating capabilities.Cellbricks Therapeutics is focused on expanding its product line with new tissue therapies targeting a range of conditions, expected to launch within the next two years. The firm plans to penetrate additional markets in North America and Asia by 2025, capitalizing on the growing demand for regenerative medicine solutions. The recent funding totaling EUR 7.00 mn will support these initiatives, including scaling production capabilities and investing in research and development to enhance their product offerings.

## Funding rounds

- Seed, Mar 25, 2026, $8.1M — ACT Venture Partners, Silicon Roundabout, SPRIND

## Investors

- ACT Venture Partners (https://capitalatlas.ai/funds/act-venture-partners) — Seed
- Silicon Roundabout (https://capitalatlas.ai/funds/silicon-roundabout) — Seed
- SPRIND — Seed